There are 19 resources available
Welcome and introduction
Presenter: Noemi Reguart Aransay
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Slides
Webcast
The importance of next-generation sequencing (NGS) testing in non-small cell lung cancer: Science, implementation and timing
Presenter: Albrecht Stenzinger
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Slides
Webcast
The availability of molecular testing in Europe and its implications for state-of-the-art care for patients with lung cancer
Presenter: Arnaud Bayle
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Slides
Webcast
Targeting molecular aberrations beyond EGFR, ALK: Clinical evidence for efficacy and ongoing research
Presenter: Jürgen Wolf
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Webcast
Concluding remarks
Presenter: Jürgen Wolf
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Webcast
Welcome and introduction
Presenter: Enriqueta Felip
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Slides
Webcast
Emerging data on the role of ADCs in the clinical care pathways for advanced NSCLC patients
Presenter: Pasi Jänne
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Slides
Webcast
Improving the safety profiles of ADCs: Early detection and optimal management of toxicities
Presenter: Maurice Pérol
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Slides
Webcast
Antibody-drug conjugates: Novel combinations with precision therapeutics and the quest for biomarkers
Presenter: Anne-Marie Dingemans
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Slides
Webcast